These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 25403210)

  • 41. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.
    Blackwell KL; Burstein HJ; Storniolo AM; Rugo HS; Sledge G; Aktan G; Ellis C; Florance A; Vukelja S; Bischoff J; Baselga J; O'Shaughnessy J
    J Clin Oncol; 2012 Jul; 30(21):2585-92. PubMed ID: 22689807
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment combinations for HER2-positive breast cancer.
    Pegram M
    Oncology (Williston Park); 2013 Apr; 27(4):258, 260. PubMed ID: 23781688
    [No Abstract]   [Full Text] [Related]  

  • 43. Role of Herceptin in primary breast cancer: views from North America and Europe.
    Leyland-Jones B; Smith I
    Oncology; 2001; 61 Suppl 2():83-91. PubMed ID: 11694792
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Trastuzumab and chemotherapy may be appropriate for small, node-negative, HER2-positive breast cancer.
    Morris PG; McArthur HL
    Oncologist; 2012; 17(10):e33; author reply e34. PubMed ID: 23104173
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [BREAST-CONSERVING SURGERY AFTER NEOADJUVANT THERAPY FOR BREAST CANCER].
    Semiglazov VF; Semiglazov VV; Petrenko OL; Komyakhov AV; Dashyan GA; Paltuev RM; Semiglazova TY; Manikhas AG; Bozhok AA; Lalak IA
    Vopr Onkol; 2015; 61(3):381-6. PubMed ID: 26242149
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Doubling down on human epidermal growth factor receptor 2.
    Krop I
    J Clin Oncol; 2012 May; 30(14):1574-6. PubMed ID: 22393081
    [No Abstract]   [Full Text] [Related]  

  • 47. Managing metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer in the older patient.
    Freedman RA; Muss HB
    J Geriatr Oncol; 2014 Jan; 5(1):2-7. PubMed ID: 24484711
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of trastuzumab-refractory, HER2-positive metastatic breast cancer.
    Hurvitz S
    Clin Adv Hematol Oncol; 2014 Apr; 12(4):260-2. PubMed ID: 25003356
    [No Abstract]   [Full Text] [Related]  

  • 49. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
    Pivot X; Romieu G; Debled M; Pierga JY; Kerbrat P; Bachelot T; Lortholary A; Espié M; Fumoleau P; Serin D; Jacquin JP; Jouannaud C; Rios M; Abadie-Lacourtoisie S; Tubiana-Mathieu N; Cany L; Catala S; Khayat D; Pauporté I; Kramar A;
    Lancet Oncol; 2013 Jul; 14(8):741-8. PubMed ID: 23764181
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative effectiveness of neoadjuvant therapy for HER2-positive breast cancer: a network meta-analysis.
    Nagayama A; Hayashida T; Jinno H; Takahashi M; Seki T; Matsumoto A; Murata T; Ashrafian H; Athanasiou T; Okabayashi K; Kitagawa Y
    J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25224562
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer.
    McArthur HL; Mahoney KM; Morris PG; Patil S; Jacks LM; Howard J; Norton L; Hudis CA
    Cancer; 2011 Dec; 117(24):5461-8. PubMed ID: 21681735
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Could trastuzumab suppress hepatitis C virus in a patient with chronic hepatitis and breast cancer?
    Tamori A; Kawajiri H; Takashima T; Motoyama H; Morikawa H; Enomoto M; Hirakawa K; Kawada N
    Am J Gastroenterol; 2011 Oct; 106(10):1865-6. PubMed ID: 21979218
    [No Abstract]   [Full Text] [Related]  

  • 53. A phase II trial of trastuzumab combined with irinotecan in patients with advanced HER2-positive chemo-refractory gastric cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group OGSG1203 (HERBIS-5).
    Sakai D; Satoh T; Kurokawa Y; Kudo T; Nishikawa K; Oka Y; Tsujinaka T; Shimokawa T; Doki Y; Furukawa H
    Jpn J Clin Oncol; 2013 Aug; 43(8):838-40. PubMed ID: 23852648
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab.
    Nishimura R; Toh U; Tanaka M; Saimura M; Okumura Y; Saito T; Tanaka T; Teraoka M; Shimada K; Katayama K; Koga T; Kurashita K; Hasegawa S; Todoroki H; Kai Y; Ohi Y; Toyoshima S; Arima N; Mitsuyama S; Tamura K
    Oncology; 2017; 93(1):51-61. PubMed ID: 28478451
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.
    Untch M; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; von Minckwitz G
    J Clin Oncol; 2010 Apr; 28(12):2024-31. PubMed ID: 20308670
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rapid tumor shrinkage with lapatinib plus capecitabine in a patient with massive liver involvement.
    Giotta F; Latorre A; Cramarossa A; Simone G; Florio C; Oliva S; Lorusso V
    Tumori; 2013; 99(6):278e-81e. PubMed ID: 24503803
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Evaluation of recurrence rates on change in hormone receptor and human epidermal growth factor receptor 2 status after neo-adjuvant chemotherapy in breast cancer patients].
    Tokunaga S; Ikeda K; Ogawa Y; Fukushima H; Inoue T; Shibata Y; Kimbara S; Katsushima U; Okada H; Tsuya A; Taira K; Daga H; Takeda K
    Gan To Kagaku Ryoho; 2014 Mar; 41(3):313-6. PubMed ID: 24743275
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients.
    Del Mastro L; Lambertini M; Bighin C; Levaggi A; D'Alonzo A; Giraudi S; Pronzato P
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1391-405. PubMed ID: 23072512
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I; Tuxen MK; Nielsen DL
    Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Information for patients. Treatment of HER2 positive early breast cancer.
    Oncology (Williston Park); 2011 Apr; 25(4 Suppl Nurse Ed):2 p following 32. PubMed ID: 25396235
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.